Facebook icon Twitter icon
Mitochondrial Biology, April 22-26, 2018, Kyoto, Japan
 
Submit abstracts for short talk consideration by March 15 for our June conferences on Neurodegenerative Diseases and Neuroinflammation, occuring in conjunction June 17-21. Progress made in human genetics has revealed increasingly more disease-associated genes for Alzheimer's disease (AD), Parkinson's disease (PD), frontotemoral dementia (FTD), amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. These discoveries have linked neurodegenerative diseases with several common key biological processes that now need further study. At the same time, tremendous strides have been made in microglial research, revealing unexpected results that challenge the traditional view of microglia as simply scavengers of the diseased CNS. The conferences on "Advances in Neurodegenerative Disease Research and Therapy" and "New Frontiers in Neuroinflammation" will:
  • Focus on emerging areas of neurodegenerative disease research including RNA metabolism, protein trafficking and innate immune responses;
  • Discuss recent advances in imaging, genetics and immunology, in particular high-throughput sequencing methods, and their implications for microglial biology research;
  • Explore the origin and functions of inflammatory glia, the blood brain barrier, myeloid cells and other signaling elements;
  • Challenge existing paradigms and provide a platform to cross-fertilize ideas and encourage new collaborations that could lead to novel mechanisms and therapeutic targets for treating neurodegenerative diseases.

The four-day conferences will feature the following confirmed speakers (additional speakers will be added, including short talks chosen from abstracts):
 
Adriano M. Aguzzi (Z3), University Hospital of Zürich, Switzerland
Bahareh Ajami (Z4), Stanford University School of Medicine, USA
Ido Amit (Z4), Weizmann Institute, Israel
Rita Balice-Gordon (Z3), Sanofi, Inc., USA
C. Frank Bennett, Ionis Pharmaceuticals, Inc. (Z3), USA
Baris Bingol (Z3), Genentech, Inc., USA
Guojun Bu (Z3), Mayo Clinic, USA
Marco Colonna (Z4), Washington University School of Medicine, USA
Ana Maria Cuervo (Z3), Albert Einstein College of Medicine, USA
Richard Daneman (Z4), University of California, San Diego, USA
Philip L. De Jager (Z4), Brigham & Women's Hospital, USA
Bart De Strooper (Z3), University College London, UK
Andrew G. Dillin (Z3), University of California, Berkeley, USA
Li Gan (Z3), Gladstone Institutes and UC San Francisco, USA
Wenbiao Gan (Z4), Skirball Institute Program of Molecular Neurobiology, USA
Aaron D. Gitler (Z3), Stanford University School of Medicine, USA
Christopher K. Glass (Z3), University of California, San Diego, USA
Alison Goate (Z3), Mount Sinai School of Medicine, USA
Melanie Greter (Z4), University of Zurich, Switzerland
Christian Haass (Z3), Ludwig-Maximilians University Munich, Germany
John Hardy (Z3), University College London, Institute of Neurology, UK
David M. Holtzman (Z3), Washington University, USA
Yadong Huang (Z3), University of California, San Francisco, USA
Bradley T. Hyman (Z3), Massachusetts General Hospital, USA
William J. Jagust (Z3), University of California, Berkeley, USA
Martin Kerschensteiner (Z4), Ludwig Maximilians University Munich, Germany
Zayd M. Khaliq, NINDS (Z3), National Institutes of Health, USA
Jonathan Kipnis (Z4), University of Virginia, USA
Robyn S. Klein (Z4), Washington University School of Medicine, USA
Irene Knuesel (Z4), Roche Innovation Center Basel, Switzerland
Albert R. La Spada (Z3), University of California, San Diego, USA
Shane Antony Liddelow (Z4), NYU Langone Medical Center, USA
Dorian B. McGavern* (Z4), National Institutes of Health, USA
Doron Merkler (Z4), University of Geneva, Switzerland
Melanie Meyer-Luehmann (Z4), University of Freiburg, Germany
Thomas Möller (Z4), Foundational Neuroscience Center, USA
Masaaki Murakami (Z4), Hokkaido University, Japan
David R. Owen (Z4), Imperial College London, UK
Francesca Peri (Z4), European Molecular Biology Laboratory, Germany
Leonard Petrucelli (Z3), Mayo Clinic Jacksonville, USA
Josef Priller (Z4), Charité – Universitätsmedizin Berlin, Germany
Marco Prinz (Z4), University of Freiburg, Germany
Francisco J. Quintana (Z4), Harvard Medical School, USA
Michal Schwartz (Z4), Weizmann Institute of Science, Israel
Morgan H. Sheng (Z3), Genentech, Inc., USA
Mikael Simons (Z4), Technische Universität München / German Center for Neurodegenerative Diseases, Germany
J. Paul Taylor, St. Jude Children's Research Hospital (Z3), USA
Leslie M. Thompson (Z3)(Z3), University of California, Irvine, USA
Li-Huei Tsai (Z3), Massachusetts Institute of Technology, USA
Tony Wyss-Coray (Z3), Stanford University School of Medicine, USA
Huaxi Xu (Z3), Sanford Burnham Prebys Medical Discovery Institute, USA
Akihiko Yoshimura (Z4), Keio University, Japan
Huda Y. Zoghbi* (Z3), HHMI/Baylor College of Medicine, USA

*Keynote Speaker
Advances in Neurodegenerative Disease Research and Therapy
joint with New Frontiers in Neuroinflammation: What Happens When CNS and Periphery Meet?
 
June 17–21, 2018
Keystone Conference Center
Keystone, Colorado, USA

Neurodegenerative Disease Scientific Organizers:
Li Gan, Gladstone Institutes and UC, San Francisco
Leonard Petrucelli, Mayo Clinic Jacksonville
Morgan H. Sheng, Genentech, Inc.

Neuroinflammation Scientific Organizers:
Marco Prinz,, University of Freiburg
Jonathan Kipnis, University of Virginia
Irene Knuesel, Roche Innovation Center Basel

Submit Abstract Submit Abstract
Register Register



PLENARY SESSIONS:

• Genetics to Epigenetics in Neurodegenerative Diseases (Z3)
• Immune Privilege, Blood-Brain Barrier and Microglia I (Z4)
• Aging in Health and Disease (Z3)
• Immune Privilege, Blood-Brain Barrier and Microglia II (Z4)
• Innate Immunity (Z3)
• Cross-Talk of Microglia with Other CNS Cells (Z4)
• Neuronal and Network Dysfunction in Neurodegeneration (Z3)
• Myeloid Cells and Neuroinflammation (Z4)
• Protein Trafficking and Degradation (Z3)
• Imaging of the Healthy and Diseased CNS (Z4)
• Disease Modeling (Z3)
• Myeloid Cells as Targets of Drug Discovery and Biomarkers (Z4)
• RNA Metabolisms and New Mechanisms of Toxicity (Z3)
• Myeloid Gene Regulation (Z4)
• Biomarker and Therapeutics (Z3)
• Microglia and CNS Diseases (Z4)


DEADLINES:

Abstract Submission:
March 15, 2018

Discounted Registration:
April 18, 2018

Registered attendees of one conference can participate in sessions of the other at no additional charge, pending space availability.

 
 
 
Who should attend?
Cell Biologists • Clinician Scientists • Geneticists • #Immunologists • Neuroscientists

 
Additional Information
  • Click here to view the Neurodegenerative Disease program and click here to download the program flyer.
  • Click here to view the Neuroinflammation program and click here to download the program flyer.
  • Deadlines are at midnight US Mountain Time.
  • Discounted registration saves 200 USD on the later fee.
  • Presenting a poster is an excellent way to gain feedback on your work. Abstracts can be submitted through May 6, 2018 for poster presentation, but those submitted by the March 15 abstract deadline will also be considered for short talk selection.
  • Please note that the first advertised meeting date is the date of arrival and registration, and the last date that of the last organized sessions.